The healthcare company's payout currently yields 3.3%, more than double the S&P 500 's ( ^GSPC 0.32%) dividend yield (near a ...

J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.

J&J's diversified business, robust pipeline, and strong free cash flow provide stability, despite legal challenges. Read more ...

Johnson & Johnson revised its fiscal year 2025 guidance. The company expects adjusted earnings of $10.80-$10.90, up from ...

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...

Johnson & Johnson is leading the S&P 500 and the Dow Jones Industrial Average after the drugmaker slashed its estimate for the impact of tariffs in 2025 and raised its outlook. The company’s stock is ...